SCHEMBL2070707

SCHEMBL2070707

Cc1cc(C)c(-c2cn(C)c3nc(N4CCOCC4)n(C)c(=O)c23)c(C)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 7/20 0.79
HTT P42858 2/20 0.45
TSHR P16473 1/20 0.39
BRD4 O60885 1/20 0.39
BRD2 P25440 1/20 0.39
BRD3 Q15059 1/20 0.39
CREBBP Q92793 1/20 0.39
LMNA P02545 2/20 0.39
STAT6 P42226 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 1/20 0.38
DPP4 P27487 1/20 0.38
GAA P10253 1/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
CYP1A2 P05177 1/20 0.37
LCK P06239 1/20 0.36
KIT P10721 1/20 0.36
SRC P12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2071923 0.90 CRHR1 (0.98) CRHR1TSHRLMNAALDH1A1MAPK1
SCHEMBL2071226 0.88 CRHR1 (1.00) CRHR1HTTTSHRLMNAALDH1A1
SCHEMBL2070607 0.77 CRHR1 (0.65) CRHR1DPP4
SCHEMBL2071874 0.75 CRHR1 (0.76) CRHR1ALDH1A1
SCHEMBL23625456 0.73 CRHR1 (0.73) CRHR1
SCHEMBL2072641 0.73 CRHR1 (0.66) CRHR1HTTTSHRLMNASMN1; SMN2
SCHEMBL2073108 0.73 CRHR1 (0.63) CRHR1ALDH1A1MAPK1LCKKIT
SCHEMBL2072338 0.73 CRHR1 (0.62) CRHR1TSHRBRD4MAPK1HSD17B10
SCHEMBL2071954 0.72 CRHR1 (1.00) CRHR1
SCHEMBL2071172 0.72 CRHR1 (0.71) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2522670-A1 Heterocyclic CRF receptor antagonists Takeda Pharmaceutical Company Limited (JP) 2012-11-14 EP disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179165-A1 Cyclic compounds CRHR1, CRHR2, MC2R CRHR1 1/4885HTT 3339/4885TSHR 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.